Literature DB >> 15066050

Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians.

Flavia Magri1, Serena Sarra, Wilma Cinchetti, Valeria Guazzoni, Marisa Fioravanti, Luca Cravello, Ettore Ferrari.   

Abstract

Melatonin secretion is an endogenous synchronizer, and it may possess some anti-aging properties. Thus we examined melatonin levels in physiological aging, in extreme senescence and in senile dementia. In healthy old (age 66-94 yr) and young subjects (age 23-39 yr) and in demented patients (age 68-91 yr) plasma melatonin was measured by radioimmunoassay in eight serial blood samples. In centenarians (age 100-107 yr) melatonin levels were estimated by assaying urinary 6-hydroxymelatonin sulfate (aMT6s) in two different urine samples collected from 08:00 to 20:00 hours and from 20:00 to 08:00 hours. These data were compared with the aMT6s excretion of old and young controls. Elderly subjects, demented or not, exhibited a flattened circadian profile of plasma melatonin, because of the suppression of the nocturnal peak. An age-related decline of the circadian amplitude of the melatonin rhythm occurred in old subjects, especially in demented individuals. Furthermore, the melatonin nocturnal peak was significantly correlated with the severity of the cognitive impairment. aMT6s urinary excretion also declined with age. However, as in young controls, in centenarians the aMT6s excretion was significantly higher at night than during the day. In conclusion, pineal melatonin secretion is affected by age and by the degree of cognitive impairment. In centenarians the maintenance of the circadian organization of melatonin secretion may suggest that the amplitude of the nocturnal peak and/or the persistence of a prevalent nocturnal secretion may be an important marker of biological age and of health status.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15066050     DOI: 10.1111/j.1600-079X.2004.00125.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  22 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

2.  The effects of melatonin versus placebo on delirium in hip fracture patients: study protocol of a randomised, placebo-controlled, double blind trial.

Authors:  Annemarieke de Jonghe; Barbara C van Munster; Hannah E van Oosten; J Carel Goslings; Peter Kloen; Carolien van Rees; Reinder Wolvius; Romuald van Velde; Marcel M Levi; Joke C Korevaar; Sophia E de Rooij
Journal:  BMC Geriatr       Date:  2011-07-05       Impact factor: 3.921

3.  Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials.

Authors:  Sheng Chen; LiGen Shi; Feng Liang; Liang Xu; Doycheva Desislava; Qun Wu; Jianmin Zhang
Journal:  Mol Neurobiol       Date:  2015-07-21       Impact factor: 5.590

4.  Melatonin reverses H2 O2 -induced premature senescence in mesenchymal stem cells via the SIRT1-dependent pathway.

Authors:  Long Zhou; Xi Chen; Tao Liu; Yihong Gong; Sijin Chen; Guoqing Pan; Wenguo Cui; Zong-Ping Luo; Ming Pei; Huilin Yang; Fan He
Journal:  J Pineal Res       Date:  2015-07-07       Impact factor: 13.007

Review 5.  Melatonin, aging, and age-related diseases: perspectives for prevention, intervention, and therapy.

Authors:  Burkhard Poeggeler
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 6.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

7.  Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence.

Authors:  Michael J Jarzynka; Deepshikha K Passey; David A Johnson; Nagarjun V Konduru; Nicholas F Fitz; Nicholas M Radio; Mark Rasenick; Susan Benloucif; Melissa A Melan; Paula A Witt-Enderby
Journal:  J Pineal Res       Date:  2008-10-28       Impact factor: 13.007

8.  Melatonin treatment in old mice enables a more youthful response to LPS in the brain.

Authors:  V M Perreau; S C Bondy; C W Cotman; K G Sharman; E H Sharman
Journal:  J Neuroimmunol       Date:  2006-10-30       Impact factor: 3.478

9.  Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease.

Authors:  Glenna A Dowling; Robert L Burr; Eus J W Van Someren; Erin M Hubbard; Jay S Luxenberg; Judy Mastick; Bruce A Cooper
Journal:  J Am Geriatr Soc       Date:  2007-12-07       Impact factor: 5.562

10.  The timing of the shrew: continuous melatonin treatment maintains youthful rhythmic activity in aging Crocidura russula.

Authors:  Elodie Magnanou; Joël Attia; Roger Fons; Gilles Boeuf; Jack Falcon
Journal:  PLoS One       Date:  2009-06-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.